H327-M18-derivative-Cpd17
picomolar BChE inhibition eqBChE IC50 = 7.44 (10-5) +/- 1.55 10-6 microM; SI = 270,000; hBChE IC50 = 1.48 (10-3) +/- 1.3 10-4 microM); COX-2 inhibitory activity (IC50 = 0.11 +/- 0.01 microM)
General
Type : Multitarget, Cyclooxygenase-2 Inhibitor, Indole, Azetidine, Carbamate, Derivative of Tryptamine
Chemical_Nomenclature : 3-((2-(6-(dimethylamino)-1H-indol-3-yl)ethyl)carbamoyl)-5-methylphenylazetidine-1-carboxylate
Canonical SMILES : C1=C(C=C2C(=C1)C(=C[N]2)CCNC(C3=C(C=C(C=C3)C)OC(N4CCC4)=O)=O)N(C)C
InChI : InChI=1S\/C24H28N4O3\/c1-16-5-7-20(22(13-16)31-24(30)28-11-4-12-28)23(29)25-10-9-17-15-26-21-14-18(27(2)3)6-8-19(17)21\/h5-8,13-15,26H,4,9-12H2,1-3H3,(H,25,29)
InChIKey : SQNOCKNAPUTADV-UHFFFAOYSA-N
Other name(s) : Compound 17
Target
References (1)
| Title : Design of N-salicyltryptamines-based highly selective BChE inhibitors to elevate brain acetylcholine, improve learning, and reduce amyloid-beta in Alzheimer's disease - Wu_2025_Eur.J.Med.Chem_302_118273 |
| Author(s) : Wu K , Yang C , Zeng J , Wu Q , Zhao Y , Hu C , Wu J , Yang H , Wang Z , Peng X |
| Ref : Eur Journal of Medicinal Chemistry , 302 :118273 , 2025 |
| Abstract : |
| PubMedSearch : Wu_2025_Eur.J.Med.Chem_302_118273 |
| PubMedID: 41161056 |